DK3337824T3 - Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf - Google Patents
Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf Download PDFInfo
- Publication number
- DK3337824T3 DK3337824T3 DK16754148.1T DK16754148T DK3337824T3 DK 3337824 T3 DK3337824 T3 DK 3337824T3 DK 16754148 T DK16754148 T DK 16754148T DK 3337824 T3 DK3337824 T3 DK 3337824T3
- Authority
- DK
- Denmark
- Prior art keywords
- bcma
- binding molecules
- bispecific antigen
- bind
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206246P | 2015-08-17 | 2015-08-17 | |
| PCT/US2016/047146 WO2017031104A1 (en) | 2015-08-17 | 2016-08-16 | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3337824T3 true DK3337824T3 (da) | 2020-08-24 |
Family
ID=56740579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16754148.1T DK3337824T3 (da) | 2015-08-17 | 2016-08-16 | Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US10072088B2 (da) |
| EP (2) | EP3757131A1 (da) |
| JP (3) | JP2018525005A (da) |
| KR (1) | KR20180040671A (da) |
| CN (1) | CN108350076B (da) |
| AR (1) | AR105724A1 (da) |
| AU (1) | AU2016308567B2 (da) |
| BR (1) | BR112018003017A2 (da) |
| CA (1) | CA2995754A1 (da) |
| CL (1) | CL2018000431A1 (da) |
| CO (1) | CO2018001524A2 (da) |
| CY (1) | CY1123297T1 (da) |
| DK (1) | DK3337824T3 (da) |
| EA (1) | EA201890513A1 (da) |
| EC (1) | ECSP18019568A (da) |
| ES (1) | ES2814550T3 (da) |
| FI (1) | FIC20230012I1 (da) |
| FR (2) | FR23C1011I1 (da) |
| HR (1) | HRP20201375T1 (da) |
| HU (2) | HUE050556T2 (da) |
| IL (2) | IL298041A (da) |
| JO (1) | JO3799B1 (da) |
| LT (2) | LT3337824T (da) |
| MA (1) | MA53750A (da) |
| MX (2) | MX2018002043A (da) |
| MY (1) | MY191325A (da) |
| NI (1) | NI201800027A (da) |
| NL (1) | NL301219I2 (da) |
| PE (1) | PE20180795A1 (da) |
| PH (1) | PH12018500361A1 (da) |
| PL (1) | PL3337824T3 (da) |
| PT (1) | PT3337824T (da) |
| RS (1) | RS60755B1 (da) |
| SI (1) | SI3337824T1 (da) |
| SV (1) | SV2018005634A (da) |
| TW (2) | TWI811023B (da) |
| UA (1) | UA127515C2 (da) |
| UY (1) | UY36859A (da) |
| WO (1) | WO2017031104A1 (da) |
| ZA (1) | ZA201801789B (da) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| WO2017143069A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| EA039084B1 (ru) * | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Антитела к tl1a и их применения |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| MX2018014228A (es) | 2016-05-20 | 2019-08-12 | Harpoon Therapeutics Inc | Proteina de union de albumina sérica de dominio unico. |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| IL265321B2 (en) | 2016-09-14 | 2024-01-01 | Teneobio Inc | CD3 binding antibodies |
| JP7254699B2 (ja) | 2016-12-21 | 2023-04-10 | テネオバイオ， インコーポレイテッド | 抗ｂｃｍａ重鎖のみ抗体 |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN110891974B (zh) | 2017-05-12 | 2021-08-06 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| SG11201912774RA (en) * | 2017-06-20 | 2020-01-30 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| CN117567624A (zh) * | 2017-06-20 | 2024-02-20 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| MA51447A (fr) * | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
| WO2019035938A1 (en) * | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| KR20200047660A (ko) | 2017-09-01 | 2020-05-07 | 다나-파버 캔서 인스티튜트 인크. | 암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드 |
| WO2019075359A1 (en) * | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHODS OF USE |
| BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| MA49911A (fr) * | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| MX2020004948A (es) | 2017-11-15 | 2020-11-11 | Novartis Ag | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. |
| CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| EP3774901A1 (en) * | 2018-03-26 | 2021-02-17 | Sutro Biopharma, Inc. | Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies |
| CN113880952A (zh) * | 2018-04-13 | 2022-01-04 | 艾菲默德有限责任公司 | 自然杀伤细胞接合抗体融合构建体 |
| JP7444790B2 (ja) * | 2018-05-16 | 2024-03-06 | ヤンセン バイオテツク，インコーポレーテツド | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 |
| EP3802611A2 (en) * | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| JP7357012B2 (ja) * | 2018-06-14 | 2023-10-05 | ２セブンティ バイオ インコーポレイテッド | 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法 |
| EP3777895A4 (en) * | 2018-06-26 | 2021-12-22 | ABL Bio Inc. | ANTI-BCMA ANTIBODIES AND USES THEREOF |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3823664A1 (en) | 2018-07-19 | 2021-05-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-bcma x anti-cd3 antibodies and uses thereof |
| TW202019477A (zh) * | 2018-07-31 | 2020-06-01 | 德商安美基研究（慕尼黑）公司 | BCMAxCD3抗體構建體之給藥方案 |
| US20220364055A1 (en) | 2018-08-31 | 2022-11-17 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| WO2020088164A1 (zh) * | 2018-11-01 | 2020-05-07 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
| CN113412124A (zh) * | 2018-12-19 | 2021-09-17 | 希望之城 | Baff-r双特异性t细胞衔接子抗体 |
| BR112021014911A2 (pt) * | 2019-02-01 | 2021-11-23 | Glaxosmithkline Intellectual Property Development Ltd | Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer |
| MX2021010150A (es) | 2019-02-25 | 2021-09-14 | Novartis Ag | Composiciones de particulas de silice mesoporosa para administracion viral. |
| BR112021016791A2 (pt) * | 2019-02-26 | 2021-11-16 | Sorrento Therapeutics Inc | Proteínas de ligação de antígenos que se ligam a bcma |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3733707A1 (en) | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| CN113966344A (zh) * | 2019-05-03 | 2022-01-21 | 细胞基因公司 | 抗-bcma抗体结合物、包含其的组合物及其制备及使用方法 |
| EP3983438A1 (en) | 2019-06-14 | 2022-04-20 | TeneoBio, Inc. | Multispecific heavy chain antibodies binding to cd22 and cd3 |
| CN110229232B (zh) * | 2019-06-19 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 双特异性抗体及其用途 |
| JP2022542088A (ja) * | 2019-07-30 | 2022-09-29 | シャンハイ ハンセン バイオメディカル カンパニー リミテッド | 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途 |
| WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
| KR20220105664A (ko) | 2019-11-26 | 2022-07-27 | 노파르티스 아게 | Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도 |
| CA3160352A1 (en) * | 2019-12-06 | 2021-06-10 | Israel Lowy | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
| US20230051266A1 (en) * | 2019-12-10 | 2023-02-16 | Abl Bio Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
| WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
| JP2023506262A (ja) * | 2019-12-16 | 2023-02-15 | ２セブンティ バイオ インコーポレイテッド | 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法 |
| IL295878A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
| MX2022010604A (es) | 2020-02-27 | 2022-09-09 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| CA3175134A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Materials and methods for modulating delta chain mediated immunity |
| TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子，其製備方法及醫藥用途 |
| CA3214992A1 (en) * | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| CN115894703A (zh) | 2020-04-29 | 2023-04-04 | 特尼奥生物股份有限公司 | 具有经修饰重链恒定区的多特异性重链抗体 |
| IL298046A (en) | 2020-05-11 | 2023-01-01 | Janssen Biotech Inc | Treatment methods for multiple myeloma |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| BR112022023392A2 (pt) | 2020-05-19 | 2022-12-20 | Janssen Biotech Inc | Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4 |
| JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Ｚｂｔｂ３２阻害剤及びその使用 |
| US20230257473A1 (en) | 2020-06-30 | 2023-08-17 | Teneobio, Inc. | Multi-specific antibodies binding to bcma |
| CN114075287B (zh) * | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化bcma抗体和bcma-car-t细胞 |
| WO2022040586A2 (en) | 2020-08-21 | 2022-02-24 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| CN116829183A (zh) | 2020-09-16 | 2023-09-29 | 美国安进公司 | 施用治疗剂量的双特异性t细胞接合分子治疗癌症的方法 |
| WO2022098771A1 (en) * | 2020-11-03 | 2022-05-12 | Ab Studio Inc. | Multispecific antibodies and uses thereof |
| KR20230090367A (ko) | 2020-11-04 | 2023-06-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법 |
| WO2022135468A1 (zh) * | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | 抗bcma×cd3双特异性抗体及其用途 |
| CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
| BR112023016121A2 (pt) | 2021-02-16 | 2023-11-28 | Janssen Pharmaceutica Nv | Anticorpo triespecífico que direciona bcma, gprc5d e cd3 |
| EP4301785A1 (en) * | 2021-03-05 | 2024-01-10 | Atreca, Inc. | Epha2 antibodies |
| CA3214594A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| KR20240004659A (ko) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법 |
| TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物 |
| KR20240014482A (ko) | 2021-05-28 | 2024-02-01 | 얀센 바이오테크 인코포레이티드 | B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma |
| CN115521381A (zh) * | 2021-06-24 | 2022-12-27 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| CN115569191A (zh) * | 2021-07-05 | 2023-01-06 | 山东新时代药业有限公司 | 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂 |
| AR126838A1 (es) | 2021-08-20 | 2023-11-22 | Novartis Ag | Métodos para preparar células que expresan receptores de antígeno quiméricos |
| WO2023076921A1 (en) * | 2021-10-27 | 2023-05-04 | Janssen Biotech, Inc. | Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue |
| US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
| WO2023086817A1 (en) * | 2021-11-10 | 2023-05-19 | Janssen Biotech, Inc. | Stable formulations comprising a bispecific bcma/cd3 antibody |
| WO2023098846A1 (zh) * | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN117003871A (zh) * | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| CN117186229B (zh) * | 2022-12-06 | 2024-03-29 | 成都赛恩吉诺生物科技有限公司 | 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| ATE462004T1 (de) | 1997-09-16 | 2010-04-15 | Centocor Inc | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| EP2301971A1 (en) | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| ES2616316T3 (es) | 2005-10-11 | 2017-06-12 | Amgen Research (Munich) Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| FI2155783T4 (fi) | 2007-04-03 | 2022-12-15 | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| PT2520590T (pt) | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| PT2352763E (pt) | 2008-10-01 | 2016-06-02 | Amgen Res (Munich) Gmbh | Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular |
| US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| NZ591134A (en) | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa) |
| ES2705714T3 (es) | 2008-10-31 | 2019-03-26 | Janssen Biotech Inc | Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| AU2011244282A1 (en) | 2010-04-20 | 2012-11-15 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| CN107903325B (zh) * | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| AU2012289926A1 (en) * | 2011-08-03 | 2014-03-13 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP3653049B1 (en) | 2012-12-14 | 2023-09-13 | OmniAb, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| EP2762497A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| JP2016507523A (ja) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体 |
-
2016
- 2016-08-16 ES ES16754148T patent/ES2814550T3/es active Active
- 2016-08-16 IL IL298041A patent/IL298041A/en unknown
- 2016-08-16 MY MYPI2018700579A patent/MY191325A/en unknown
- 2016-08-16 MA MA053750A patent/MA53750A/fr unknown
- 2016-08-16 US US15/237,889 patent/US10072088B2/en active Active
- 2016-08-16 EA EA201890513A patent/EA201890513A1/ru unknown
- 2016-08-16 CA CA2995754A patent/CA2995754A1/en active Pending
- 2016-08-16 TW TW111126438A patent/TWI811023B/zh active
- 2016-08-16 JO JOP/2016/0184A patent/JO3799B1/ar active
- 2016-08-16 JP JP2018508695A patent/JP2018525005A/ja active Pending
- 2016-08-16 LT LTEP16754148.1T patent/LT3337824T/lt unknown
- 2016-08-16 SI SI201630895T patent/SI3337824T1/sl unknown
- 2016-08-16 KR KR1020187007297A patent/KR20180040671A/ko not_active Application Discontinuation
- 2016-08-16 CN CN201680060812.2A patent/CN108350076B/zh active Active
- 2016-08-16 MX MX2018002043A patent/MX2018002043A/es unknown
- 2016-08-16 PT PT167541481T patent/PT3337824T/pt unknown
- 2016-08-16 BR BR112018003017-1A patent/BR112018003017A2/pt active Search and Examination
- 2016-08-16 RS RS20201050A patent/RS60755B1/sr unknown
- 2016-08-16 WO PCT/US2016/047146 patent/WO2017031104A1/en active Application Filing
- 2016-08-16 PL PL16754148T patent/PL3337824T3/pl unknown
- 2016-08-16 AU AU2016308567A patent/AU2016308567B2/en active Active
- 2016-08-16 HU HUE16754148A patent/HUE050556T2/hu unknown
- 2016-08-16 EP EP20177664.8A patent/EP3757131A1/en active Pending
- 2016-08-16 UA UAA201802674A patent/UA127515C2/uk unknown
- 2016-08-16 DK DK16754148.1T patent/DK3337824T3/da active
- 2016-08-16 TW TW105126031A patent/TWI777924B/zh active
- 2016-08-16 PE PE2018000262A patent/PE20180795A1/es unknown
- 2016-08-16 EP EP16754148.1A patent/EP3337824B1/en active Active
- 2016-08-17 AR ARP160102519A patent/AR105724A1/es unknown
- 2016-08-17 UY UY0001036859A patent/UY36859A/es active IP Right Grant
-
2018
- 2018-02-11 IL IL257468A patent/IL257468B2/en unknown
- 2018-02-15 PH PH12018500361A patent/PH12018500361A1/en unknown
- 2018-02-16 CO CONC2018/0001524A patent/CO2018001524A2/es unknown
- 2018-02-16 SV SV2018005634A patent/SV2018005634A/es unknown
- 2018-02-16 NI NI201800027A patent/NI201800027A/es unknown
- 2018-02-16 MX MX2022006650A patent/MX2022006650A/es unknown
- 2018-02-16 CL CL2018000431A patent/CL2018000431A1/es unknown
- 2018-03-14 EC ECIEPI201819568A patent/ECSP18019568A/es unknown
- 2018-03-16 ZA ZA201801789A patent/ZA201801789B/en unknown
-
2020
- 2020-08-28 CY CY20201100810T patent/CY1123297T1/el unknown
- 2020-08-28 HR HRP20201375TT patent/HRP20201375T1/hr unknown
-
2021
- 2021-07-30 JP JP2021126285A patent/JP7194240B2/ja active Active
-
2022
- 2022-12-08 JP JP2022196582A patent/JP2023027228A/ja active Pending
-
2023
- 2023-02-22 NL NL301219C patent/NL301219I2/nl unknown
- 2023-02-22 FI FIC20230012C patent/FIC20230012I1/fi unknown
- 2023-02-22 FR FR23C1011C patent/FR23C1011I1/fr active Active
- 2023-02-22 HU HUS2300011C patent/HUS2300011I1/hu unknown
- 2023-02-22 FR FR23C1012C patent/FR23C1012I1/fr active Active
- 2023-02-23 LT LTPA2023509C patent/LTPA2023509I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3337824T3 (da) | Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf | |
| HK1255971A1 (zh) | 抗psma抗體、結合psma及cd3的雙特異性抗原結合分子及其用途 | |
| DK3328893T3 (da) | Bispecifikke antistofkonstruktioner, der binder mesothelin og cd3 | |
| ZA201901066B (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| DK3328892T3 (da) | Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3 | |
| DK3328889T3 (da) | Bispecifikke antistofkonstruktioner, der binder dll3 og cd3 | |
| HK1254966A1 (zh) | 雙特異性抗cd19xcd3 t細胞活化性抗原結合份子 | |
| HK1252856A1 (zh) | 雙特異性抗ceaxcd3 t細胞活化性抗原結合分子 | |
| HK1254068A1 (zh) | 雙特異性t細胞活化性抗原結合分子 | |
| IL259082A (en) | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof | |
| DK3370768T3 (da) | Antistoffer som specifikt binder pd-1 og anvendelser deraf | |
| DK3223845T3 (da) | Heterodimere antistoffer, der binder cd3 og cd20 | |
| DK3353212T3 (da) | Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf | |
| DK3411402T3 (da) | Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner | |
| DK3221356T3 (da) | T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3 | |
| DK3356411T3 (da) | Bispecifikke antistoffer, der er specifikke for PD1 og TIM3 | |
| DK3177643T3 (da) | Bispecifikke T-celle-aktiverende antigenbindende molekyler | |
| DK3122781T3 (da) | Bispecifikke antistoffer, der binder til cd38 og cd3 | |
| DK3778641T3 (da) | Bispecifikke antigenbindingsmolekyler, der binder CD3 og CD20, og anvendelser deraf | |
| DK3283524T3 (da) | BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3 | |
| DK3200822T3 (da) | Bindingsmolekyler, i særdeleshed antistoffer, der binder til l1cam (cd171) |